2021 U.S.-Booked Air Volume: $4.4 million
Global Online Booking Tool: Concur
Consolidated U.S. TMC: BCD
Pharmaceutical giant Sanofi in 2021 spent $4.4 million on
U.S.-booked air travel, down from $9.5 million in 2020 and about only 8 percent
of 2019 volumes. With business travel back on the rise as the company returned
to the office during the second quarter of 2022, this year’s air spend is
expected to rebound to $25 million, about half of pre-pandemic levels. Full
recovery is expected in between two to five years.
Since the pandemic, some travel team members were
transferred to other departments and use of third-party consultants was
decreased or discontinued. The company in 2021 revisited its chauffeured
transportation network agreements and implemented Uber for Business and Parking
Spot as alternatives to black-car service or rental cars because of supply
shortages and increased costs. Sanofi also updated its travel policy in 2022,
simplifying it by removing meal and hotel caps and offering guidelines instead.
The hotel program has static and dynamic rates, as well as rate shopping tools.
The company is looking at synergies between meetings and
transient travel and does not have pre-trip approval and does not plan to
implement. Virtual options are leveraged for internal meetings, but
customer-facing meeting largely remain in-person.
Sanofi reported Scope 3 tons of CO2 emissions for 2021
business travel as nearly 38,000, down significantly from the 87,400 in 2020
and more than 168,500 reported in 2019, used as its baseline year. The company
has introduced a policy for sales rep travel, including vehicle buying and
eco-driving courses, that cut CO2 emissions by 47 percent between 2019 and
2021. Sanofi also is looking into sustainable aviation fuel investments.
The company in 2021 reported net sales of €37.8 billion, up
from €36 billion in 2020 and €36.1 billion in 2019. Total employees as of Dec.
31, 2021, were nearly 95,450, down from 99,400 in 2020.